#1 Clinical Trials Search in Europe

2′-O-(2-Methoxyethyl) Modified Antisense Oligonucleotide Targeting Plp1 Pre-Mrna

This article discusses the ongoing clinical trials of ION356, a novel drug designed to treat Pelizaeus-Merzbacher Disease (PMD). ION356 is a 2′-O-(2-Methoxyethyl) modified antisense oligonucleotide targeting PLP1 pre-mRNA. The Phase 1b study aims to evaluate the safety, tolerability, and effectiveness of this intrathecally administered medication in young male patients with PMD.

Table of Contents

What is ION356?

ION356 is a new medication being developed to treat Pelizaeus-Merzbacher Disease (PMD). It is classified as a 2′-O-(2-methoxyethyl) modified antisense oligonucleotide that targets the PLP1 pre-mRNA.[1] In simpler terms, ION356 is a specially designed molecule that aims to modify how a specific gene (PLP1) is processed in the body, potentially helping patients with PMD.

Target Condition: Pelizaeus-Merzbacher Disease

Pelizaeus-Merzbacher Disease (PMD) is a rare genetic disorder that affects the central nervous system. It primarily impacts the brain and spinal cord, causing problems with movement, balance, and intellectual development. PMD is caused by mutations in the PLP1 gene, which is responsible for producing a protein essential for the proper formation of myelin, the protective covering around nerve fibers.[1]

How ION356 Works

ION356 is designed to target the PLP1 gene’s pre-mRNA (a precursor to the final genetic instructions). By interacting with this pre-mRNA, ION356 aims to modify how the PLP1 gene is expressed, potentially correcting or mitigating the effects of the genetic mutation that causes PMD. This approach is part of a cutting-edge field of medicine called antisense oligonucleotide therapy.[1]

Current Research on ION356

ION356 is currently being studied in a Phase 1b clinical trial. This study, known as ION356-CS1, is designed to evaluate several important aspects of the drug:[1]

  • Safety and tolerability: Researchers want to ensure that ION356 doesn’t cause harmful side effects in patients with PMD.
  • Pharmacokinetics (PK): This refers to how the drug moves through the body, including how it’s absorbed, distributed, and eliminated.
  • Pharmacodynamics: This looks at how the drug affects the body and whether it produces the desired therapeutic effects.

The medication is administered intrathecally, which means it’s injected directly into the fluid surrounding the brain and spinal cord. This method allows the drug to reach the central nervous system more effectively.[1]

Eligibility Criteria for the Study

The current study has specific criteria for participants, including:[1]

  • A confirmed diagnosis of PMD with a specific genetic mutation (PLP1 gene duplication)
  • Male patients between 2 and 17 years old
  • Clinical symptoms and brain imaging consistent with PMD
  • Ability to comply with study requirements, including travel and procedures

There are also several exclusion criteria, such as having more than 2 copies of the PLP1 gene, certain medical conditions that might interfere with the study, or previous treatments that could affect the results.

Safety and Monitoring

Patient safety is a top priority in this study. The researchers will closely monitor participants for any side effects or adverse events. This includes:[1]

  • Regular check-ups and laboratory tests
  • Neurological exams
  • ECG (heart monitoring)
  • Monitoring of vital signs
  • Analysis of blood, urine, and cerebrospinal fluid samples

Potential Benefits and Considerations

While ION356 shows promise, it’s important to understand that this is an early-stage clinical trial. The main goals are to assess safety and gather initial data on how the drug works in the body. It’s not yet known if ION356 will provide significant benefits to patients with PMD.

Participating in this study involves several considerations:

  • Regular visits to the study center
  • Multiple medical procedures, including intrathecal injections and MRI scans
  • Potential risks associated with a new, experimental treatment
  • The possibility of contributing to the development of a new treatment for PMD

As research continues, more information will become available about ION356 and its potential as a treatment for Pelizaeus-Merzbacher Disease. Patients and families interested in this treatment should discuss it with their healthcare providers to understand if it might be appropriate for their situation.[1]

Aspect Details
Drug Name ION356 (2′-O-(2-Methoxyethyl) Modified Antisense Oligonucleotide Targeting PLP1 Pre-mRNA)
Trial Phase Phase 1b
Target Condition Pelizaeus-Merzbacher Disease (PMD)
Main Objective Evaluate safety and tolerability of ION356
Secondary Objective Characterize CSF and plasma pharmacokinetics
Administration Route Intrathecal injection
Eligible Participants Males aged 2-17 years with confirmed PMD diagnosis
Key Inclusion Criteria PLP1 gene duplication, consistent clinical phenotype and brain imaging
Key Exclusion Criteria More than 2 PLP1 gene copies, recent major surgery, MRI contraindications
Primary Endpoints Incidence of adverse events, changes in laboratory assessments, neurological exams, and vital signs

FAQ

  • What is Pelizaeus-Merzbacher Disease (PMD)? Pelizaeus-Merzbacher Disease is a rare genetic disorder affecting the nervous system. It is characterized by problems with movement, balance, and coordination due to abnormal myelin formation in the brain.
  • Who is eligible for the ION356 clinical trial? The trial is open to male patients between 2 and 17 years old with a confirmed diagnosis of PMD caused by PLP1 gene duplication. Participants must have a clinical phenotype and brain imaging consistent with PMD.
  • How is ION356 administered in the trial? ION356 is administered intrathecally, which means it is injected directly into the spinal canal to reach the cerebrospinal fluid (CSF) surrounding the brain and spinal cord.
  • What are the main objectives of the ION356 clinical trial? The primary objective is to evaluate the safety and tolerability of ION356. Secondary objectives include characterizing the drug's pharmacokinetics (how the body processes the drug) in both CSF and plasma.
  • Are there any key exclusion criteria for the trial? Yes, some key exclusion criteria include having more than 2 copies of the PLP1 gene, recent major surgery, contraindications to MRI, and previous treatment with certain types of drugs or therapies that might interfere with the study results.

Ongoing Clinical Trials on 2′-O-(2-Methoxyethyl) Modified Antisense Oligonucleotide Targeting Plp1 Pre-Mrna

  • Study on the Safety and Effects of ION356 for Patients with Pelizaeus-Merzbacher Disease

    Recruiting

    1 1
    Investigated diseases:
    Investigated drugs:
    France Germany The Netherlands

Glossary

  • Pelizaeus-Merzbacher Disease (PMD): A rare genetic disorder affecting the nervous system, characterized by problems with movement, balance, and coordination due to abnormal myelin formation in the brain.
  • Intrathecal administration: A method of drug delivery where medication is injected directly into the spinal canal to reach the cerebrospinal fluid (CSF) surrounding the brain and spinal cord.
  • Antisense oligonucleotide: A short strand of synthetic DNA or RNA that can bind to specific genetic sequences to modify gene expression or protein production.
  • PLP1 gene: The gene responsible for producing proteolipid protein 1, which is essential for proper myelin formation in the central nervous system.
  • Pharmacokinetics (PK): The study of how a drug moves through the body, including its absorption, distribution, metabolism, and excretion.
  • Cerebrospinal fluid (CSF): A clear, colorless fluid that surrounds the brain and spinal cord, providing protection, nutrients, and waste removal.
  • Treatment-emergent adverse events (TEAEs): Any unfavorable medical occurrence that appears or worsens after starting a medical treatment.
  • Serious adverse events (SAEs): Any adverse event that results in death, is life-threatening, requires hospitalization, or causes significant disability.
  • Lumbar puncture (LP): A medical procedure where a needle is inserted into the lower back to collect cerebrospinal fluid or administer medication.
  • Magnetic Resonance Imaging (MRI): A non-invasive imaging technique that uses magnetic fields and radio waves to create detailed images of the body's internal structures.

References

  1. http://clinicaltrials.eu/trial/study-on-the-safety-and-effects-of-ion356-for-patients-with-pelizaeus-merzbacher-disease/